Dexcom Inc Stock Current Valuation
| D1EX34 Stock | BRL 8.45 0.45 5.62% |
Valuation analysis of DexCom Inc helps investors to measure DexCom's intrinsic value by examining its available valuation indicators, including the cash flow records, the balance sheet account changes and income statement patterns.
Undervalued
Today
Please note that DexCom's price fluctuation is somewhat reliable at this time. Calculation of the real value of DexCom Inc is based on 3 months time horizon. Increasing DexCom's time horizon generally increases the accuracy of value calculation and significantly improves the predictive power of the methodology used.
Since DexCom is currently traded on the exchange, buyers and sellers on that exchange determine the market value of DexCom Stock. However, DexCom's intrinsic value may or may not be the same as its current market price, in which case there is an opportunity to profit from the mispricing, assuming the market price will eventually merge with its intrinsic value. | Historical | Market 8.45 | Real 8.83 | Hype 8.45 |
The real value of DexCom Stock, also known as its intrinsic value, is the underlying worth of DexCom Inc Company, which is reflected in its stock price. It is based on DexCom's financial performance, growth prospects, management team, or industry conditions. The intrinsic value of DexCom's stock can be calculated using various methods such as discounted cash flow analysis, price-to-earnings ratio, or price-to-book ratio. That value may differ from its current market price, which is determined by supply and demand factors such as investor sentiment, market trends, or news.
Estimating the potential upside or downside of DexCom Inc helps investors to forecast how DexCom stock's addition to their portfolios will impact the overall performance. We also use other valuation drivers to help us estimate the true value of DexCom more accurately as focusing exclusively on DexCom's fundamentals will not take into account other important factors: DexCom Inc Company Current Valuation Analysis
DexCom's Enterprise Value is a firm valuation proxy that approximates the current market value of a company. It is typically used to determine the takeover or merger price of a firm. Unlike Market Cap, this measure takes into account the entire liquid asset, outstanding debt, and exotic equity instruments that the company has on its balance sheet. When a takeover occurs, the parent company will have to assume the target company's liabilities but will take possession of all cash and cash equivalents.
Current DexCom Current Valuation | 4.96 B |
Most of DexCom's fundamental indicators, such as Current Valuation, are part of a valuation analysis module that helps investors searching for stocks that are currently trading at higher or lower prices than their real value. If the real value is higher than the market price, DexCom Inc is considered to be undervalued, and we provide a buy recommendation. Otherwise, we render a sell signal.
Enterprise Value can be a useful tool to compare companies with different capital structures. Long term liability and current cash or cash equivalents can have a huge impact on market valuation of a given company.
| Competition |
In accordance with the recently published financial statements, DexCom Inc has a Current Valuation of 4.96 B. This is 65.47% lower than that of the Healthcare sector and 36.38% lower than that of the Diagnostics & Research industry. The current valuation for all Brazil stocks is 70.16% higher than that of the company.
DexCom Current Valuation Peer Comparison
Stock peer comparison is one of the most widely used and accepted methods of equity analyses. It analyses DexCom's direct or indirect competition against its Current Valuation to detect undervalued stocks with similar characteristics or determine the stocks which would be a good addition to a portfolio. Peer analysis of DexCom could also be used in its relative valuation, which is a method of valuing DexCom by comparing valuation metrics of similar companies.DexCom is currently under evaluation in current valuation category among its peers.
DexCom Fundamentals
| Return On Equity | 31.66 | |||
| Return On Asset | 5.37 | |||
| Profit Margin | 24.45 % | |||
| Operating Margin | 15.90 % | |||
| Current Valuation | 4.96 B | |||
| Shares Outstanding | 4.84 B | |||
| Price To Earning | 2.07 X | |||
| Price To Book | 2.97 X | |||
| Price To Sales | 129.36 X | |||
| Revenue | 2.17 B | |||
| Gross Profit | 1.28 B | |||
| EBITDA | 415.8 M | |||
| Net Income | 530.6 M | |||
| Cash And Equivalents | 2.58 B | |||
| Cash Per Share | 26.72 X | |||
| Total Debt | 1.89 B | |||
| Debt To Equity | 0.95 % | |||
| Current Ratio | 5.78 X | |||
| Book Value Per Share | 19.68 X | |||
| Cash Flow From Operations | 409 M | |||
| Earnings Per Share | 28.32 X | |||
| Number Of Employees | 5.5 K | |||
| Beta | 0.74 | |||
| Market Capitalization | 280.7 B | |||
| Z Score | 88.8 |
About DexCom Fundamental Analysis
The Macroaxis Fundamental Analysis modules help investors analyze DexCom Inc's financials across various querterly and yearly statements, indicators and fundamental ratios. We help investors to determine the real value of DexCom using virtually all public information available. We use both quantitative as well as qualitative analysis to arrive at the intrinsic value of DexCom Inc based on its fundamental data. In general, a quantitative approach, as applied to this company, focuses on analyzing financial statements comparatively, whereas a qaualitative method uses data that is important to a company's growth but cannot be measured and presented in a numerical way.
Please read more on our fundamental analysis page.
Also Currently Popular
Analyzing currently trending equities could be an opportunity to develop a better portfolio based on different market momentums that they can trigger. Utilizing the top trending stocks is also useful when creating a market-neutral strategy or pair trading technique involving a short or a long position in a currently trending equity.| ZLAB | Zai Lab | |
| ASLE | AerSale Corp | |
| ATS | AT S Austria |
Additional Information and Resources on Investing in DexCom Stock
When determining whether DexCom Inc is a strong investment it is important to analyze DexCom's competitive position within its industry, examining market share, product or service uniqueness, and competitive advantages. Beyond financials and market position, potential investors should also consider broader economic conditions, industry trends, and any regulatory or geopolitical factors that may impact DexCom's future performance. For an informed investment choice regarding DexCom Stock, refer to the following important reports:Check out Investing Opportunities to better understand how to build diversified portfolios, which includes a position in DexCom Inc. Also, note that the market value of any company could be closely tied with the direction of predictive economic indicators such as signals in nation. You can also try the Portfolio Center module to all portfolio management and optimization tools to improve performance of your portfolios.